KYMR

ANALYST NOTE: KYMR (Kymera Therapeutics, Inc.) Date: 2026-06-13

(1) Structural Readiness The stock is currently trading at $108.12, which sits 7.2% below the conservative entry level of $116.46. The setup is in a "watchlist" state with a confirmed breakout signal having fired previously, indicating the stock has cleared a significant structural base. While the current price is in a pullback relative to the breakout point, the presence of the confirmed breakout signal suggests the underlying structure remains intact rather than broken. The current Average True Range (ATR) is 6.3%, categorized as "very high," indicating elevated volatility and active trading interest compared to the 5.5% ATR recorded at the time of the initial breakout. This suggests the stock is in a high-conviction, high-volatility phase where price action is being driven by significant news flow rather than passive accumulation. The structure is best described as a confirmed breakout that has entered a consolidation or pullback phase following a sharp move, rather than a base still forming.

(2) The Thesis Layer The primary secular thesis driving this name is exposure to the Biotech & GLP-1 → Immunology & Inflammation theme. Kymera is a direct beneficiary within this sector, operating as a clinical-stage biopharmaceutical company focused on targeted protein degradation. The company's role is to provide novel mechanisms of action (molecular glue degraders) that address unmet needs in moderate-to-severe inflammatory diseases. The evidence suggests a high-confidence direct link to this theme, as the company's lead assets (KT-621 and KT-485) are specifically designed to treat conditions like atopic dermatitis and asthma, which represent massive, underserved patient populations. The thesis is reinforced by the broader market context where the introduction of new mechanisms historically expands immunology markets by enabling access to additional patient populations.

(3) The Business Kymera Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapeutics that selectively degrade disease-causing proteins using the body's natural cellular process, known as targeted protein degradation. The company's business model relies on internal R&D to advance its pipeline, supplemented by strategic collaborations that provide non-dilutive capital and milestone payments.

As of the most recent data available on June 13, 2026, the company's operational status is defined by the following:

• Pipeline Progress: The company recently completed enrollment in the Phase 2b BROADEN2 trial for its lead candidate, KT-621, in atopic dermatitis. Management expects to share top-line data for this study by year-end 2026. Additionally, the Phase 2b asthma trial (BREADTH) is ongoing, with data expected in late 2027.
• Strategic Partnerships:
• Sanofi: Kymera is collaborating on KT-485, an IRAK4 degrader. As of June 9, 2026, the first patient was dosed in a Phase 1 study for hidradenitis suppurativa, triggering a $20 million milestone payment. Sanofi plans to advance KT-485 into clinical testing in 2026.
• Gilead: In June 2025, Kymera entered an exclusive option and license agreement with Gilead Sciences to develop oral molecular glue degraders targeting CDK2. As of the March 31, 2026, filing, the company recognized $34.4 million in revenue under this agreement. If Gilead exercises the option, Kymera is entitled to a $45.0 million payment and up to $665.0 million in potential milestones.
• Financial Position: As of March 31, 2026, the company held $1,546 million in cash, cash equivalents, and marketable securities. Management stated in the February 26, 2026 earnings transcript that the company ended December with $1.6 billion, providing a runway into 2029. The company believes its current cash position is sufficient to fund operations and capital expenditure requirements for at least twelve months from the issuance of the financial statements.

(4) The Archetype and Conviction Kymera fits the Quality Compounder archetype. This classification is driven by the company's ability to advance a differentiated technology platform (targeted protein degradation) into multiple high-value clinical programs while maintaining a robust balance sheet that supports a long runway.

• Valuation & Financials: The financial spine indicates a pre-revenue growth profile with forward consensus EPS estimates of -3.48 for FY1 and -4.30 for FY2. This is consistent with a clinical-stage biotech where value is derived from asset progression rather than current earnings.
• Conviction Drivers:
• Thesis Strength: The alignment with the Immunology & Inflammation secular theme is direct and high-conviction, addressing a market of over 140 million patients in the US, EU, and Japan.
• Evidence Quality: The evidence base is robust, featuring multiple primary sources (earnings transcripts, SEC filings) confirming pipeline milestones, partnership payments, and cash runway.
• Structural Quality: The ATR at the time of the initial breakout was 5.5% (high), indicating strong structural quality. The current ATR of 6.3% (very high) reflects the market's reaction to the recent enrollment completion news, suggesting active institutional interest.
• Rerating Potential: The acceleration of the KT-621 timeline (enrollment completed six months ahead of schedule) and the initiation of KT-485 dosing provide multiple catalysts for re-rating the asset from a "clinical risk" to a "near-term data" profile.

(5) Invalidation, Strengthening, and Gaps

• What Would Strengthen the Case: Positive top-line data from the BROADEN2 (AD) trial in late 2026; successful initiation of Phase 3 trials for KT-621; additional milestone payments from Sanofi or Gilead; or a strategic acquisition offer.
• What Would Invalidate the Case: Negative or inconclusive data from the BROADEN2 trial; a significant reduction in cash runway due to unexpected burn rates; or a failure to secure the Gilead option exercise.
• Gaps in Evidence: While the cash runway is clear, there is no specific evidence in the provided set regarding the exact burn rate per quarter or the specific timeline for the Gilead option exercise decision beyond the agreement terms. Additionally, while the Phase 1 data for KT-621 in Japanese adults is presented, the specific efficacy metrics for the broader Phase 2b population are not yet available as of this date.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: high Key evidence: Completed enrollment in Phase 2b BROADEN2 trial for KT-621 with data expected by year-end 2026; $1.6 billion cash balance providing runway into 2029; $20 million milestone payment triggered from Sanofi collaboration upon KT-485 dosing. Key risks: Binary outcome risk from late-2026 Phase 2b data readout; potential dilution if cash burn accelerates beyond current projections; competitive landscape in the immunology space. Sizing hint: Position size should account for the very high current ATR (6.3%) and the binary nature of the upcoming data event. Expected path: Stock likely to consolidate or trend higher as the market prices in the accelerated timeline and the certainty of the late-2026 data readout, with potential for further upside if Phase 3 initiation is confirmed. Expected horizon: 6 to 12 months, aligning with the expected top-line data release in late 2026. Failure mode to watch: Disappointing or negative top-line results from the BROADEN2 trial in atopic dermatitis.